SMO antagonists activate the Ca2+-AMPK signal [65,112], which is involved in the type II non-canonical Hh signal [65], and they are believed to affect energy metabolism in muscle, adipose tissue, the liver, and the pancreas, leading to weight loss and muscle side effects in SMO antagonists, such as convulsions, alopecia, fatigue, and dysgeusia, occurring in 19–33% of patients with a mortality rate of 2–11% [113]. The gene discussed is SMO; the disease is alopecia.